These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20542448)

  • 1. Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient.
    Cerussi AE; Tanamai VW; Mehta RS; Hsiang D; Butler J; Tromberg BJ
    Acad Radiol; 2010 Aug; 17(8):1031-9. PubMed ID: 20542448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy.
    Cerussi AE; Tanamai VW; Hsiang D; Butler J; Mehta RS; Tromberg BJ
    Philos Trans A Math Phys Eng Sci; 2011 Nov; 369(1955):4512-30. PubMed ID: 22006904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.
    Tromberg BJ; Zhang Z; Leproux A; O'Sullivan TD; Cerussi AE; Carpenter PM; Mehta RS; Roblyer D; Yang W; Paulsen KD; Pogue BW; Jiang S; Kaufman PA; Yodh AG; Chung SH; Schnall M; Snyder BS; Hylton N; Boas DA; Carp SA; Isakoff SJ; Mankoff D;
    Cancer Res; 2016 Oct; 76(20):5933-5944. PubMed ID: 27527559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy.
    O'Sullivan TD; Leproux A; Chen JH; Bahri S; Matlock A; Roblyer D; McLaren CE; Chen WP; Cerussi AE; Su MY; Tromberg BJ
    Breast Cancer Res; 2013 Feb; 15(1):R14. PubMed ID: 23433249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.
    Tank A; Peterson HM; Pera V; Tabassum S; Leproux A; O'Sullivan T; Jones E; Cabral H; Ko N; Mehta RS; Tromberg BJ; Roblyer D
    Breast Cancer Res; 2020 Mar; 22(1):29. PubMed ID: 32169100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
    J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.
    Bahri S; Chen JH; Mehta RS; Carpenter PM; Nie K; Kwon SY; Yu HJ; Nalcioglu O; Su MY
    Ann Surg Oncol; 2009 Jun; 16(6):1619-28. PubMed ID: 19333654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment.
    Cochran JM; Busch DR; Leproux A; Zhang Z; O'Sullivan TD; Cerussi AE; Carpenter PM; Mehta RS; Roblyer D; Yang W; Paulsen KD; Pogue B; Jiang S; Kaufman PA; Chung SH; Schnall M; Snyder BS; Hylton N; Carp SA; Isakoff SJ; Mankoff D; Tromberg BJ; Yodh AG
    J Biomed Opt; 2018 Oct; 24(2):1-11. PubMed ID: 30338678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study.
    Jakubowski DB; Cerussi AE; Bevilacqua F; Shah N; Hsiang D; Butler J; Tromberg BJ
    J Biomed Opt; 2004; 9(1):230-8. PubMed ID: 14715078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
    Chen JH; Feig B; Agrawal G; Yu H; Carpenter PM; Mehta RS; Nalcioglu O; Su MY
    Cancer; 2008 Jan; 112(1):17-26. PubMed ID: 18000804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric monitoring of chemotherapy treatment response in locally advanced breast cancer using quantitative ultrasound and diffuse optical spectroscopy.
    Tran WT; Childs C; Chin L; Slodkowska E; Sannachi L; Tadayyon H; Watkins E; Wong SL; Curpen B; El Kaffas A; Al-Mahrouki A; Sadeghi-Naini A; Czarnota GJ
    Oncotarget; 2016 Apr; 7(15):19762-80. PubMed ID: 26942698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy.
    Ueda S; Saeki T
    Breast Cancer; 2014 Nov; 21(6):776-9. PubMed ID: 24795075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Performances of breast magnetic resonance imaging in the context of neoadjuvant chemotherapy for breast cancer to predict pathological complete response].
    Brisson C; Diguisto C; Vildé A; Body G; Arbion F; Leveque J; Ouldamer L
    J Gynecol Obstet Hum Reprod; 2017 Feb; 46(2):147-154. PubMed ID: 28403971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI evaluation of residual breast cancer after neoadjuvant chemotherapy: influence of patient, tumor and chemotherapy characteristics on the correlation with pathological response.
    Diguisto C; Ouldamer L; Arbion F; Vildé A; Body G
    Anticancer Res; 2015 Jan; 35(1):581-5. PubMed ID: 25550606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal optical monitoring of blood flow in breast tumors during neoadjuvant chemotherapy.
    Cochran JM; Chung SH; Leproux A; Baker WB; Busch DR; DeMichele AM; Tchou J; Tromberg BJ; Yodh AG
    Phys Med Biol; 2017 Jun; 62(12):4637-4653. PubMed ID: 28402286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy.
    Cerussi A; Hsiang D; Shah N; Mehta R; Durkin A; Butler J; Tromberg BJ
    Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4014-9. PubMed ID: 17360469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study.
    Delille JP; Slanetz PJ; Yeh ED; Halpern EF; Kopans DB; Garrido L
    Radiology; 2003 Jul; 228(1):63-9. PubMed ID: 12775851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to neoadjuvant treatment of invasive ductal breast carcinomas including outcome evaluation: MRI analysis by an automatic CAD system in comparison to visual evaluation.
    Böttcher J; Renz DM; Zahm DM; Pfeil A; Fallenberg EM; Streitparth F; Maurer MH; Hamm B; Engelken FJ
    Acta Oncol; 2014 Jun; 53(6):759-68. PubMed ID: 24299492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.
    Ueda S; Roblyer D; Cerussi A; Durkin A; Leproux A; Santoro Y; Xu S; O'Sullivan TD; Hsiang D; Mehta R; Butler J; Tromberg BJ
    Cancer Res; 2012 Sep; 72(17):4318-28. PubMed ID: 22777823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.